Effect of fondaparinux anticoagulants on D-dimer levels in Covid-19 patients
DOI:
https://doi.org/10.46542/pe.2023.234.233237Keywords:
Anticoagulant, COVID-19, D-dimer, Fondaparinux, Severity levelAbstract
Background: Anticoagulants can prevent thromboembolic activities, improve prognosis, and reduce the mortality rate in Covid-19 patients with coagulopathy.
Objective: To analyse the effect of Fondaparinux in decreasing D-dimer levels, and to determine the correlation between patient characteristics, disease severity, and D-dimer levels.
Methods: This is a single-centre retrospective cohort study using the medical records of Covid-19 in-patients who were ≥ 17 years old, on Fondaparinux 2.5 mg OD and had D-dimer measurement pre-and post-five days-Fondaparinux therapy during hospitalisation at referral general hospital in Bengkulu, Indonesia between April 2020 and December 2021. The data were assessed to evaluate the differences in the pre-post D-dimer levels, the relationship between patient characteristics and disease severity, and the relationship between disease severity and D-dimer levels.
Results: A total of thirty-six patients were included in this study, of which 52.78% were males and 44.44% were aged 46-55 years old. Furthermore, 88.89% had comorbidity, and 55.55% had moderate severity. There was a significant decrease in D-dimer levels in all disease severity (p < 0.05). Patient characteristics and disease severity were not associated with D-dimer depletion (p > 0.05).
Conclusion: Fondaparinux reduced the D-dimer levels in all severity of Covid-19 patients.
References
Azizah, N.F., Faizah, R.N., Primasanti, D., Khuluqiyah, K., Prihantini., & Romadhian, I.G. (2022). Efektifitas penggunaan enoxaparin dan fondaparinux sebagai antikoagulan, 18(1), 57–64. https://doi.org/10.22146/farmaseutik.v18i1.71913
Barnes, G.D., Burnett, A., Allen, A., Blumenstein, M., Clark, N.P., Cuker, A., Dager, W.E., Deitelzweig, S.B., Ellsworth, S., Garcia, D., Kaatz, S., & Minichiello, T. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 50(1), 72–81. https://doi.org/10.1007/s11239-020-02138-z
Becker, R.C. (2020). COVID-19 update: Covid-19-associated coagulopathy. Journal of Thrombosis and Thrombolysis, 50(1), 54–67. https://doi.org/10.1007/s11239-020-02134-3
Bwire, G.M. (2020). Coronavirus: Why men are more vulnerable to Covid-19 than women? SN Comprehensive Clinical Medicine, 2(7), 874–876. https://doi.org/10.1007/s42399-020-00341-w
Cen, Y., Chen, X., Shen, Y., Zhang, X.H., Lei, Y., Xu, C., Jiang, W.R., Xu, H.T., Chen, Y., Zhu, J., Zhang, L.L., & Liu, Y.H. (2020). Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—A multi-centre observational study. Clinical Microbiology and Infection, 26(9), 1242–1247. https://doi.org/10.1016/j.cmi.2020.05.041
Cheng, Y.J., Liu, Z.H., Yao, F.J., Zeng, W.T., Zheng, D.D., Dong, Y.G., & Wu, S.H. (2013). Current and former smoking and risk for venous thromboembolism: A systematic review and meta-analysis. PLoS Medicine, 10(9). https://doi.org/10.1371/journal.pmed.1001515
Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N. & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. International Journal of Environmental Research and Public Health, 17(8). https://doi.org/10.3390/ijerph17082690
Donat F., Duret J.P., Santoni A., Cariou R., Necciari J., Magnani H., & de Greef R., (2020). The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002, 41(2), 1-9.
Dong, W.J., Qian, H.J., Qian, Y., Zhou, L., & Hu, S.L. (2016). Fondaparinux vs. enoxaparin for preventing venous thromboembolism after total hip replacement: A meta-analysis. Experimental and Therapeutic Medicine, 12(2), 969–974. https://doi.org/10.3892/etm.2016.3351
Elviani, R., Anwar, C., & Januar Sitorus, R. (2021). Gambaran usia pada kejadian Covid-19. Jambi Medical Journal “Jurnal Kedokteran Dan Kesehatan,” 9(1), 204–209. https://doi.org/10.22437/jmj.v9i1.11263
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Kementerian Kesehatan RI. (2018). Hasil utama RISKESDAS 2018. https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf
Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., Kaptein, F.H.J., van Paassen, J., Stals, M.A.M., Huisman, M.V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 191(January), 145–147. https://doi.org/10.1016/j.thromres.2020.04.013
Li Y., Jerkic M., Slutsky A.S., & Zhang H., (2020), Molecular mechanisms of sex bias differences in COVID-19 mortality. Critical Care, 24, 405 https://doi.org/10.1186/s13054-020-03118-8
Mishra, Y., Pathak, B.K., Mohakuda, S.S., Tilak, T., Sen, S., P, H., Singh, R., & Singh, A.R. (2020). Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. Diabetes & metabolic syndrome, 14(6), 1927–1930 https://doi.org/10.1016/j.dsx.2020.09.035
Pagana K.D, Pagana T.J., & Pagana T.N. (2019). Mosby’s Diagnostic & laboratory test reference. 14th ed. Elsevier.
Pivonello, R., Auriemma, R.S., Pivonello, C., Isidori, A.M., Corona, G., Colao, A., & Millar, R.P. (2021). Sex disparities in COVID-19 severity and outcome: Are men weaker or women stronger? Neuroendocrinology, 111(11), 1066–1085. https://doi.org/10.1159/000513346
Rosovsky, R.P., Sanfilippo, K.M., Wang, T.F., Rajan, S.K., Shah, S., Martin, K.A., Ní Áinle, F., Huisman, M., Hunt, B.J., Kahn, S.R., Kevane, B., Lee, A.Y.Y., McLintock, C., & Baumann Kreuziger, L. (2020). Anticoagulation practice patterns in COVID‐19: A global survey. Research and Practice in Thrombosis and Haemostasis, 4(6), 969–983 https://doi.org/10.1002/rth2.12414
Ruhyat, E. (2021). Perilaku merokok di masa Covid-19. Jurnal Sehat Masada, 15(1), 180–187 https://doi.org/10.38037/jsm.v15i1.178
Russo, V., Cardillo, G., Viggiano, G. V., Mangiacapra, S., Cavalli, A., Fontanella, A., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., Sacco, C., Lodigiani, C., Castaldo, G., & Di Micco, P. (2020). Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: A multicenter Italian observational study. Frontiers in Medicine, 7, 4–8 https://doi.org/10.3389/fmed.2020.569567
William, H.A., Hardigaloeh, A.T., Supit, A.I., & Handriyani, H. (2020). Koagulopati pada coronavirus disease -2019 (COVID-19): Tinjauan pustaka. Intisari Sains Medis, 11(3), 749–756 https://doi.org/10.15562/ism.v11i3.766
Wolff, D., Nee S., Hickey N.S., & Marschollek M., (2021). Risk factors for Covid-19 severity and fatality: A structured literature review. Infection, 49, 15-28 https://doi.org/10.1007/s15010-020-01509-1
World Health Organisation. (2019). WHO global report on Trends in the Prevalence of tobacco use 2000–2025, third edition.
